

1. PRODUCT AND COMPANY IDENTIFICATION

1.1 Product identifiers

Product name : Tamoxifen citrate

Product Number : 10-1256

Brand : Focus Biomolecules

CAS-No. : 54965- 24-1

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : For Laboratory Research Use Only

1.3 Details of the supplier of the safety data sheet

Company : Focus Biomolecules

400 Davis Drive, Suite 600 Plymouth Meeting, PA 19462

Telephone : +1 855-362-8721

E-mail : support@focusbiomolecules.com

1.4 Emergency telephone number

Emergency Phone # : +1-215-565-5428

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)

Acute toxicity, Oral (Category 4), H302 Carcinogenicity (Category 1B), H350 Reproductive toxicity (Category 1B), H360

For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2 GHS Label elements, including precautionary statements

Pictogram



Signal word Hazard Danger

statement(s)

H302 Harmful if swallowed. H350 May cause cancer.

H360 May damage fertility or the unborn child.

Precautionary statement(s)

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

Wash skin thoroughly after handling.

P264 Do not eat, drink or smoke when using this product.
P270 Use personal protective equipment as required.

P281 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. IF

P301 + P312 exposed or concerned: Get medical advice/ attention.

P308 + P313

Tamoxifen Citrate Page 1 of 8

P330 Rinse mouth.
P405 Store locked up.

P501 Dispose of contents/ container to an approved waste disposal plant.

2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Synonyms : (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene

Formula : $C_{26}H_{29}NO \cdot C_{6}H_{8}O_{7}$

Molecular weight : 563.64 g/mol CAS-No. : 54965- 24-1 EC-No. : 259-415-2

Hazardous components

I WE WOULD COMPONENT.				
Component	Classification	Concentration		
(Z)-[2-[4-(1,2-Diphenylbut-1-enyl)phenoxy]ethyl]dimethylammonium dihydrogen 2-				
hydroxypropane-1,2,3-tricarboxylate				
	Acute Tox. 4; Carc. 1B; Repr.	-		
	1B; H302, H350, H360			

For the full text of the H-Statements mentioned in this Section, see Section 16.

4. FIRST AID MEASURES

4.1 Description of first aid measures

General advice

Consult a physician. Show this safety data sheet to the doctor in attendance. Move out of dangerous area.

If inhaled

If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

In case of skin contact

Wash off with soap and plenty of water. Consult a physician.

In case of eye contact

Flush eyes with water as a precaution.

If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3 Indication of any immediate medical attention and special treatment needed

No data available

5. FIREFIGHTING MEASURES

5.1 Extinguishing media

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2 Special hazards arising from the substance or mixture

No data available

5.3 Advice for firefighters

Wear self-contained breathing apparatus for firefighting if necessary.

Tamoxifen Citrate Page 2 of 8

5.4 Further information

No data available

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.

For personal protection see section 8.

6.2 Environmental precautions

Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

6.3 Methods and materials for containment and cleaning up

Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

Reference to other sections

6.4 For disposal see section 13.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Avoid contact with skin and eyes. Avoid formation of dust and aerosols.

Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection. For precautions see section 2.2.

7.2 Conditions for safe storage, including any incompatibilities Keep

container tightly closed in a dry and well-ventilated place.

Recommended storage temperature -20°C

Storage class (TRGS 510): 6.1D: Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

7.3 Specific end use(s)

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Components with workplace control parameters

Contains no substances with occupational exposure limit values.

8.2 Exposure controls

Appropriate engineering controls

Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

Personal protective equipment

Eye/face protection

Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Full contact

Material: Nitrile rubber

Minimum layer thickness: 0.11 mm

Break through time: 480 min

Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)

Splash contact

Material: Nitrile rubber

Tamoxifen Citrate Page 3 of 8

Minimum layer thickness: 0.11 mm Break through time: 480 min

Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)

data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: EN374 If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It should not be construed as offering an approval for any specific use scenario.

Body Protection

Complete suit protecting against chemicals, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Respiratory protection

Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Control of environmental exposure

Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties a)

Appearance Form: solid		rm: solid	
b)	Odour	No data available	
c)	Odour Threshold	No data available	
d)	pН	No data available	
e)	Melting point/freezing point	No data available	
f)	Initial boiling point and boiling range	No data available	
g)	Flash point	No data available	
h)	Evaporation rate	No data available	
i)	Flammability (solid, gas)	No data available	
j)	Upper/lower flammability or explosive limits	No data available	
k)	Vapour pressure	No data available	
1)	Vapour density	No data available	
m)	Relative density	No data available	
n)	Water solubility	No data available	
o)	Partition coefficient: n-octanol/water	No data available	
p)	Auto-ignition temperature	No data available	
q)	Decomposition temperature	No data available	
r)	Viscosity	No data available	
s)	Explosive properties	No data available	
t)	Oxidizing properties	No data available	

Tamoxifen Citrate Page 4 of 8

9.2 Other safety information

No data available

10. STABILITY AND REACTIVITY

10.1 Reactivity

No data available

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions No

data available

10.4 Conditions to avoid

No data available

10.5 Incompatible materials

Strong oxidizing agents

10.6 Hazardous decomposition products

Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx) Other decomposition products - No data available

In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION 11.1

Information on toxicological effects

Acute toxicity

LD50 Oral - Rat - 1,190 mg/kg

Remarks: Behavioral:Somnolence (general depressed activity). Respiratory disorder Nutritional and Gross

Metabolic: Weight loss or decreased weight gain.

Inhalation: No data available

Dermal: No data available

No data available

Skin corrosion/irritation

No data available

Serious eye damage/eye irritation

No data available

Respiratory or skin sensitisation

No data available

Germ cell mutagenicity

No data available

Carcinogenicity

This is or contains a component that has been reported to be carcinogenic based on its IARC, OSHA, ACGIH, NTP, or EPA classification.

Possible human carcinogen

IARC: 1 - Group 1: Carcinogenic to humans ((Z)-[2-[4-(1,2-Diphenylbut-1-

enyl)phenoxy]ethyl]dimethylammonium dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate)

ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a

carcinogen or potential carcinogen by ACGIH.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known

or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a

carcinogen or potential carcinogen by OSHA.

Tamoxifen Citrate Page 5 of 8

Reproductive toxicity

May cause congenital malformation in the fetus.

Presumed human reproductive toxicant

May cause reproductive disorders.

Specific target organ toxicity - single exposure

No data available

Specific target organ toxicity - repeated exposure

No data available

Aspiration hazard

No data available

Additional Information

RTECS: KH2387000

To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

Stomach - Irregularities - Based on Human Evidence

Stomach - Irregularities - Based on Human Evidence

12. ECOLOGICAL

INFORMATION 12.1 Toxicity

No data available

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6 Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Product

Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.

Contaminated packaging

Dispose of as unused product.

14. TRANSPORT INFORMATION

DOT (US)

Not dangerous goods

IMDG

Not dangerous goods

IATA

Not dangerous goods

Tamoxifen Citrate Page 6 of 8

15. REGULATORY INFORMATION

SARA 302 Components

No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards

Acute Health Hazard, Chronic Health Hazard

Massachusetts Right To Know Components

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components

CAS-No. Revision Date (Z)-[2-[4-(1,2-Diphenylbut-1-enyl)phenoxy]ethyl]dimethylammonium dihydrogen 2-

hydroxypropane-1,2,3-tricarboxylate

New Jersey Right To Know Components

CAS-No. Revision Date

(Z)-[2-[4-(1,2-Diphenylbut-1- 54965-24-1

enyl)phenoxy]ethyl]dimethylammonium dihydrogen 2-

hydroxypropane-1,2,3-tricarboxylate

California Prop. 65 Components

WARNING: This product contains a chemical known to the State of California to cause birth defects or other reproductive harm.

CAS-No. Revision Date 2007-09-28

(Z)-[2-[4-(1,2-Diphenylbut-1-

enyl)phenoxy]ethyl]dimethylammonium dihydrogen 2-

hydroxypropane-1,2,3-tricarboxylate

16. OTHER INFORMATION

Full text of H-Statements referred to under sections 2 and 3.

Acute Tox. Acute toxicity
Carc. Carcinogenicity
H302 Harmful if swallowed.
H350 May cause cancer.

H360 May damage fertility or the unborn child.

Repr. Reproductive toxicity

HMIS Rating

Health hazard: Chronic 1
Health Hazard: *
Flammability: 0
Physical Hazard 0

NFPA Rating

Health hazard: Fire 1
Hazard: Reactivity 0
Hazard: 0

Further information

Copyright 2019 Focus Biomolecules. License granted to make unlimited paper copies for internal use only. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. Materials are intended for Laboratory Use only and must be used by qualified technicians. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to

Tamoxifen Citrate Page 7 of 8

appropriate safety precautions. It does not represent any guarantee of the properties of the product. Focus Biomolecules and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product.

Version: 1.0 Revision Date: 5/28/2019

Tamoxifen Citrate Page 8 of 8